The FDA Has Accepted Under Priority Review AstraZeneca's Supplemental Biologics License Application For Imfinzi (Durvalumab) For Limited-Stage Small Cell Lung Cancer Whose Disease Has Not Progressed Following Platinum-based Concurrent Chemoradiotherapy, With Prescription Drug User Fee Act Date Anticipated During Fourth Quarter Of 2024
Author: Benzinga Newsdesk | August 15, 2024 04:55am